150 related articles for article (PubMed ID: 26390988)
1. 5-alpha-reductase inhibitors and the risk of diabetes mellitus: A nationwide population-based study.
Lee SS; Yang YW; Tsai TH; Kuo YH; Chuang HY; Lee CC; Hsieh TF
Prostate; 2016 Jan; 76(1):41-7. PubMed ID: 26390988
[TBL] [Abstract][Full Text] [Related]
2. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.
Hsieh TF; Yang YW; Lee SS; Lin TH; Liu HH; Tsai TH; Chen CC; Huang YS; Lee CC
PLoS One; 2015; 10(3):e0119694. PubMed ID: 25803433
[TBL] [Abstract][Full Text] [Related]
3. 5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec.
Lin W; Lee S; Wu J; Kuo Y; Hsieh T
PLoS One; 2017; 12(4):e0175356. PubMed ID: 28394903
[TBL] [Abstract][Full Text] [Related]
4. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.
Shih HJ; Huang CJ; Lin JA; Kao MC; Fan YC; Tsai PS
Prostate; 2018 Feb; 78(2):113-120. PubMed ID: 29119583
[TBL] [Abstract][Full Text] [Related]
5. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study.
Man KM; Chen KB; Chen HY; Chiang JH; Su YC; Man SS; Xie DD; Wang Y; Zhang ZQ; Bi LK; Zhang T; Yu DX; Chen WC
Medicine (Baltimore); 2018 Sep; 97(39):e12459. PubMed ID: 30278528
[TBL] [Abstract][Full Text] [Related]
6. Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients.
Eaddy M; Kruep E; Lunacsek O; Goodwin B
Expert Opin Pharmacother; 2012 Dec; 13(18):2593-600. PubMed ID: 23163741
[TBL] [Abstract][Full Text] [Related]
7. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
8. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
[TBL] [Abstract][Full Text] [Related]
9. Positive Association of Male Overactive Bladder Symptoms and Androgen Deprivation: A Nationwide Population-based Cohort Study.
Li JR; Wang SS; Lin CH; DE Groat WC; Cheng CL
Anticancer Res; 2019 Jan; 39(1):305-311. PubMed ID: 30591473
[TBL] [Abstract][Full Text] [Related]
10. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR
Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197
[TBL] [Abstract][Full Text] [Related]
11. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
12. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
13. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
14. Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia.
Chung JS; Seo WI; Oh CK; Kim SC; Park MC; Park SH; Yu J; Lee CH; Kim W; Park TY; Min KS; Chung JI
Investig Clin Urol; 2020 Jan; 61(1):67-74. PubMed ID: 31942465
[TBL] [Abstract][Full Text] [Related]
15. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
[TBL] [Abstract][Full Text] [Related]
16. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Lin VC; Liao CH; Kuo HC
Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
[TBL] [Abstract][Full Text] [Related]
17. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men.
Chang J; Choi S; Kim K; Park SM
J Clin Med; 2019 May; 8(5):. PubMed ID: 31121994
[TBL] [Abstract][Full Text] [Related]
19. Risk of rhabdomyolysis from 5-α reductase inhibitors.
Welk B; McArthur E; Ordon M; Dirk J; Dixon S; Garg AX
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):351-355. PubMed ID: 29368380
[TBL] [Abstract][Full Text] [Related]
20. Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea.
Yeon B; Suh AY; Choi E; Kim B; Noh E; Chung SY; Han SY
PLoS One; 2022; 17(3):e0265169. PubMed ID: 35294468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
